Search results for "CyclinE"

showing 10 items of 194 documents

Epidemiology and Pattern of Resistance of Gram-Negative Bacteria Isolated from Blood Samples in Hospitalized Patients: A Single Center Retrospective …

2021

Background: Blood culturing remains the mainstream tool to inform an appropriate treatment in hospital-acquired bloodstream infections and to diagnose any bacteremia. Methods: A retrospective investigation on the prevalence of Gram-negative bacteria (GNB) and their resistance in hospitalized patients by age, sex, and units from blood cultures (BCs) was conducted from January 2018 to April 2020 at Sant’Elia hospital, Caltanissetta, southern Italy. We divided the patient age range into four equal intervals. Results: Multivariate demographic and microbiological variables did not show an association between bacteria distributions and gender and age. The distribution by units showed a higher pre…

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaCarbapenemmedicine.medical_specialtymedicine.drug_classAntibioticsTigecyclineRM1-950BiochemistryMicrobiologyArticlelaw.inventionAntibiotic resistancelawInternal medicineMDRmedicinePharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsbacteriasurvival timebiologybusiness.industrybiology.organism_classificationmedicine.diseaseIntensive care unitinfectionAcinetobacter baumanniiInfectious DiseasesBacteria Infection MDR Survival timeBacteremiaColistinTherapeutics. Pharmacologybusinessmedicine.drugAntibiotics
researchProduct

Optimal treatment of leptospirosis: queries and projections.

2006

Although the global burden of leptospirosis remains enormous and new aspects of the disease are constantly recognised, little progress has been achieved in the field of leptospirosis therapeutics and queries regarding the utility of antibiotics in the late severe form of the disease remain. From the currently existing data, conclusions on the efficacy of antibiotic administration in severe or late disease cannot easily be drawn, since clinical trials have different selection criteria and may focus on Leptospira serovars with different virulence. However, as a rule the benefit of the doubt should apply. Moreover, new options, such as ceftriaxone, have a superior safety profile to penicillin.…

Microbiology (medical)medicine.medical_specialtymedicine.drug_classAntibioticsDiseaseLeptospirosiMiceLeptospiramedicineAnimalsHumansPharmacology (medical)LeptospirosisIntensive care medicineAntibacterial agentLeptospirabiologybusiness.industryOptimal treatmentCeftriaxoneGeneral Medicinemedicine.diseasebiology.organism_classificationPenicillinLeptospirosisAnti-Bacterial AgentsClinical trialTreatmentSafety profileInfectious DiseasesDoxycyclineImmunologybusinessInternational journal of antimicrobial agents
researchProduct

Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model.

2011

Although polymicrobial infections, such as peri-implantitis or periodontitis, were postulated in the literature to be caused by synergistic effects of bacteria, these effects remain unclear looking at antibiotic susceptibility. The aim of this study is to compare the antibiotic susceptibilities of pure cultures and definite cocultures.Laboratory strains of Aggregatibacter actinomycetemcomitans (Aa) (previously Actinobacillus actinomycetemcomitans), Capnocytophaga ochracea (Co), and Parvimonas micra (Pm) (previously Peptostreptococcus micros) were cultivated under anaerobic conditions, and their susceptibilities to 10 antibiotics (benzylpenicillin G, ampicillin, amoxicillin, ampicillin/sulba…

MoxifloxacinMinocyclineAzithromycinAzithromycinAggregatibacter actinomycetemcomitanschemistry.chemical_compoundActinobacillus InfectionsAnti-Infective AgentsAmpicillinAcetamidesbiologyCoinfectionPenicillin GSulbactamAnti-Bacterial AgentsSulbactamQuinolinesPeriodonticsCapnocytophagamedicine.drugFluoroquinolonesAmoxicillin-Potassium Clavulanate CombinationMicrobiologyClavulanic acidMetronidazoleDrug Resistance BacterialmedicineHumansParvimonas micraPeriodontitisGram-Positive Bacterial InfectionsOxazolidinonesAza Compoundsbusiness.industryPeptostreptococcusAggregatibacter actinomycetemcomitansLinezolidAmoxicillinbiochemical phenomena metabolism and nutritionAmoxicillinbacterial infections and mycosesbiology.organism_classificationPeri-ImplantitisCoculture TechniqueschemistryLinezolidImmunologyMicrobial InteractionsAmpicillinbusinessGram-Negative Bacterial InfectionsJournal of periodontology
researchProduct

Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-k…

2006

The stem cell leukemia gene SCL, also known as TAL-1, encodes a basic helix-loop-helix transcription factor expressed in erythroid, myeloid, megakaryocytic, and hematopoietic stem cells. To be able to make use of the unique tissue-restricted and spatio-temporal expression pattern of the SCL gene, we have generated a knock-in mouse line containing the tTA-2S tetracycline transactivator under the control of SCL regulatory elements. Analysis of this mouse using different tetracycline-dependent reporter strains demonstrated that switchable transgene expression was restricted to erythrocytes, megakaryocytes, granulocytes, and, importantly, to the c-kit-expressing and lineage-negative cell fracti…

MyeloidErythrocytesGenotypeTransgeneImmunologyMice TransgenicBiologyBiochemistryMiceMegakaryocyteGenes Reporterhemic and lymphatic diseasesProto-Oncogene ProteinsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsT-Cell Acute Lymphocytic Leukemia Protein 1DNA PrimersRegulation of gene expressionReporter geneBase SequenceCell BiologyHematologyTetracyclineFlow CytometryMolecular biologyRecombinant ProteinsHematopoiesisHaematopoiesisProto-Oncogene Proteins c-kitmedicine.anatomical_structureGene Expression RegulationBone marrowStem cellMegakaryocytesGranulocytesBlood
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells

2012

The multidrug resistance-associated protein 2 (MRP2/ABCC2) is involved in the efflux of endogenous and xenobiotic substrates, including several anticancer and antiviral drugs. The functional consequences of ABCC2 protein variants remain inconsistent, which may be due to shortcomings of the in vitro assays used. To study systematically the functional consequences of nonsynonymous ABCC2 variants, we used a novel “Screen and Insert” (ScIn) technology to achieve stable and highly reproducible expression of 13 ABCC2 variants in HT1080 cells. Western blotting revealed lower (30–65%) ABCC2 expression for D333G, R1174H, and R1181L as compared with wild type (WT; 100%), whereas the linked variant V1…

Nonsynonymous substitutionFibrosarcomaMutation MissenseATP-binding cassette transporterBiologyCell Line TumorGeneticsHumansGenetics (clinical)GeneticsAsianMultidrug resistance-associated protein 2Endoplasmic reticulumChloraminesWild typeGenetic VariationTetracyclineMolecular biologyMultidrug Resistance-Associated Protein 2Recombinant ProteinsBlack or African AmericanBlotHEK293 CellsGene Expression RegulationHaplotypesHT1080EffluxMultidrug Resistance-Associated ProteinsHuman Mutation
researchProduct

Conventional induction and post-remission therapy in APL: have we arrived?

2014

Since the introduction of all-trans-retinoic acid, the use of this molecularly targeted treatment in combination with anthracycline-based chemotherapy has completely changed the prognosis of acute promyelocytic leukemia (APL) turning it into the most curable acute myeloid leukemia. Also, the use of risk-adapted protocols has optimized the drug combination and the most appropriate dose intensity for each subset of patients classified according to both risk of relapse and vulnerability to drug toxicity. Recent developments have included the investigation of the role of arsenic trioxide (ATO) as front-line treatment after its success in relapsed APL, both to minimize or even omit the use of cy…

OncologyAcute promyelocytic leukemiaDrugmedicine.medical_specialtyHarringtoninesAnthracyclinemedia_common.quotation_subjectmedicine.medical_treatmentClinical BiochemistryTretinoinPharmacologyArsenicalsTargeted therapyMaintenance Chemotherapychemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcuteInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicAnthracyclinesRelapse riskArsenic trioxidemedia_commonChemotherapyClinical Trials as Topicbusiness.industryMercaptopurineDaunorubicinRemission InductionMyeloid leukemiaOxidesmedicine.diseaseConsolidation ChemotherapyMethotrexateOncologychemistryMitoxantronebusinessHomoharringtonineIdarubicinBest practiceresearch. Clinical haematology
researchProduct

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…

2015

Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…

OncologyAdultAdjuvant taxanesCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmenteducationBreast NeoplasmsDocetaxelDisease-Free SurvivalPooled analysisBreast cancerBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIn patientAnthracyclinesOestrogen receptorProspective StudiesAgedER positivebusiness.industryMiddle Agedmedicine.diseaseImmunohistochemistryPooled analysisKi-67 AntigenOncologyDocetaxelBreast international groupChemotherapy AdjuvantFemaleTaxoidsbusinessAdjuvantKi67medicine.drug
researchProduct

Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph node…

2014

Abstract Aim Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/Taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: (1)Are there differences in survival dependent on chemotherapy regimens in stratified by number of positive lymph nodes/grading (G)/hormone receptor-status (HR)/T-stage? (2)Is it possible to attribute these effects to chemotherapy by only investigating patients who received 100% guideline-conform surgery, radiotherapy and endocrine therapy? Methods This is a German multi-centre (17 participating hospitals all certified as breast cancer centres) re…

OncologyAdultBridged-Ring CompoundsCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAxillary lymph nodesAnthracyclineDose-dense chemotherapyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAnthracyclinesAgedRetrospective StudiesAged 80 and overChemotherapyAnalysis of VarianceTaxanebusiness.industryRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTreatment OutcomeOncologyChemotherapy AdjuvantLymphatic MetastasisPractice Guidelines as TopicFemaleTaxoidsGuideline AdherencebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Mitomycin 'C' and vinorelbine as second line chemotherapy for metastatic breast carcinoma

1994

Aims and background Patients with metastatic breast carcinoma resistant to first line chemotherapy may require further treatment. Results o second line chemotherapy are still largerly unsatisfactory. For this reason a phase II study on the combination of mitomycin C and vinorelbine was carried out. Methods Forty patients with anthracycline pretreated metastatic breast cancer were treated with a combination of mitomycin C 10 mg/m2 i.v. on day 1, and vinorelbine 25 mg/m2 i.v. on days 1 and 8. This cycle was repeated every 28 days. Responses were evaluated according to the WHO criteria. Results A major objective response was recorded in 16 cases (40%; 95% confidence limits 32%-48%), with 2 pat…

OncologyAdultCancer Researchmedicine.medical_specialtyAnthracyclineMitomycinPhases of clinical researchBreast NeoplasmsVinorelbineVinblastineGastroenterologyDrug Administration Schedule030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedLeukopeniabusiness.industryMitomycin CCarcinomaVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemedicine.symptombusinessProgressive diseasemedicine.drug
researchProduct